Balofloxacin
Grundinformationen
- CAS
127294-70-6- Standard-SMILES
CNC1CCCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2OC)C1- InChIKey
MGQLHRYJBWGORO-UHFFFAOYSA-N- Summenformel
- C20H24FN3O4
- Durchschnittliche Molmasse
- 389,4 g/mol
- Monoisotopische Masse
- 389,17508442
Namen und Bezeichner
- Bevorzugter Name
- Balofloxacin
- IUPAC
- 1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(methylamino)piperidin-1-yl]-4-oxoquinoline-3-carboxylic acid
- Englischer Name
- Balofloxacin
- Summenformel
- C20H24FN3O4
- Molmasse
- 389.42
Namen und Synonyme
Balofloxacin127294-70-6Q-RoxinDTXSID5046695balofloxacinebalofloxacinoQ022B63JPM1-cyclopropyl-6-fluoro-8-methoxy-7-[3-(methylamino)piperidin-1-yl]-4-oxoquinoline-3-carboxylic acidDTXCID30266953-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-(methylamino)-1-piperidinyl)-4-oxo-3-Quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-[3-(methylamino)-1-piperidinyl]-4-oxo-1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylaminopiperidin-1-yl)-4-oxoquinoline-3-carboxylic acid
Weitere Namen anzeigen
q35Barlow of sandBALOFLOXACIN 98.5%Balofloxacin425.46Balofloxacin, >=99%Balofloxacin hydrateBalofloxacin USP/EP/BPCypermethrin Impurity 4Balofloxacin, 10 mM in DMSO
balofloxacinumBalofoxBazucin1-cyclopropyl-6-fluoro-8-methoxy-7-(3-(methylamino)piperidin-1-yl)-4-oxoquinoline-3-carboxylic acidRefChem:1163831-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methylaminopiperidine-1-yl)-4-oxoquinoline-3-carboxylic acid1-Cyclopropyl-6-fluoro-8-methoxy-7-(3-(methylamino)piperidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acidBalofloxacin [INN]
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 0,6
- Polarare Oberfläche (TPSA)
- 82,1 Ų
- H-Brücken-Donoren
- 2
- H-Brücken-Akzeptoren
- 8
- Frei drehbare Bindungen
- 5
- Schwere Atome
- 28
- Formalladung
- 0
- Komplexität
- 668
Physikochemische Eigenschaften
- Schmelzpunkt
- 137 °C · 137°C
- Siedepunkt
- 608.3 · 608.3±55.0 °C(Predicted)
- Dichte
- 1.4 · 1.40±0.1 g/cm3(Predicted)
- storage temp.
- 2 · Keep in dark place,Inert atmosphere,2-8°C
- Löslichkeit
- 2 O · H2O : < 0.1 mg/mL (insoluble)DMSO : 0.67 mg/mL (1.72 mM; Need ultrasonic)
- pka
- 6.44 · 6.44±0.50(Predicted)
- Aggregatzustand
- Solid
- Farbe
- White to off-white
- BRN
- 8362117 · 8362117
- InChI
- InChI=1S/C20H24FN3O4/c1-22-11-4-3-7-23(9-11)17-15(21)8-13-16(19(17)28-2)24(12-5-6-12)10-14(18(13)25)20(26)27/h8,10-12,22H,3-7,9H2,1-2H3,(H,26,27)
- InChIKey
- MGQLHRYJBWGORO-UHFFFAOYSA-N
- SMILES
- N1(C2CC2)C2=C(C=C(F)C(N3CCCC(NC)C3)=C2OC)C(=O)C(C(O)=O)=C1
- CAS Datenbank
- 127294 · 127294-70-6(CAS DataBase Reference)
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Sicherheitsdaten
- wgk
- 3
- Speicherklasse
- 11 - Combustible Solids
Chemie und Industrie
Pharmakologische Informationen
MeSH Pharmacological Classification
Substances that inhibit the growth or reproduction of BACTERIA.
Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II.
Anwendungen
BeschreibungBalofloxacin, a novel orally-active fluoroquinolone antibiotic, was introduced in South Korea for the treatment of urinary tract infections (UTI). It can be synthetized by reaction of 3-(methylamino)piperidine with the classical 4-quinolone-3-carboxylic acid template. In vitro antibacterial activity of balofloxacin against gram-positive bacteria (Staphylococcus aureus including methicillin-resistant S. aureus, Staphylococcus epidermis, Streptococcus pneumonia, Streptococcus pyrogenes) was almost equal to that of sparfloxacin or tosufloxacin, in contrast its activity against gram-negative bacteria was 2 times or more lower. In clinical trials, balofloxacin was well tolerated and showed comparable efficacy to ofloxacin in patients with UTls. After oral administration, balofloxacin was well absorbed, and was primarily eliminated unchanged in the urine with an elimination half-life of approximately 8 h. In animal studies, balofloxacin did not exhibit any phototoxicity.
VerwendenBalofloxacin is quinolone antibiotic, inhibiting the synthesis of bacterial DNA by interference with the enqyme DNA gyrase.
Vor- und nachgelagerte Produkte
Vorgelagerte Rohstoffe
Zugehörige Reaktionen
2
Notizen zur Verbindung
Wird geladen…